148 related articles for article (PubMed ID: 12463730)
1. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers.
Martin PD; Kemp J; Dane AL; Warwick MJ; Schneck DW
J Clin Pharmacol; 2002 Dec; 42(12):1352-7. PubMed ID: 12463730
[TBL] [Abstract][Full Text] [Related]
2. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
Martin PD; Dane AL; Schneck DW; Warwick MJ
Clin Ther; 2003 Feb; 25(2):459-71. PubMed ID: 12749507
[TBL] [Abstract][Full Text] [Related]
3. The effect of fluconazole on the pharmacokinetics of rosuvastatin.
Cooper KJ; Martin PD; Dane AL; Warwick MJ; Schneck DW; Cantarini MV
Eur J Clin Pharmacol; 2002 Nov; 58(8):527-31. PubMed ID: 12451430
[TBL] [Abstract][Full Text] [Related]
4. Effect of itraconazole on the pharmacokinetics of rosuvastatin.
Cooper KJ; Martin PD; Dane AL; Warwick MJ; Schneck DW; Cantarini MV
Clin Pharmacol Ther; 2003 Apr; 73(4):322-9. PubMed ID: 12709722
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
Martin PD; Warwick MJ; Dane AL; Cantarini MV
Clin Ther; 2003 Aug; 25(8):2215-24. PubMed ID: 14512129
[TBL] [Abstract][Full Text] [Related]
6. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.
Martin PD; Warwick MJ; Dane AL; Hill SJ; Giles PB; Phillips PJ; Lenz E
Clin Ther; 2003 Nov; 25(11):2822-35. PubMed ID: 14693307
[TBL] [Abstract][Full Text] [Related]
7. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor.
Martin PD; Dane AL; Nwose OM; Schneck DW; Warwick MJ
J Clin Pharmacol; 2002 Oct; 42(10):1116-21. PubMed ID: 12362926
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
Martin PD; Mitchell PD; Schneck DW
Br J Clin Pharmacol; 2002 Nov; 54(5):472-7. PubMed ID: 12445025
[TBL] [Abstract][Full Text] [Related]
9. The effect of erythromycin on the pharmacokinetics of rosuvastatin.
Cooper KJ; Martin PD; Dane AL; Warwick MJ; Raza A; Schneck DW
Eur J Clin Pharmacol; 2003 May; 59(1):51-6. PubMed ID: 12682802
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects.
Cooper KJ; Martin PD; Dane AL; Warwick MJ; Raza A; Schneck DW
Br J Clin Pharmacol; 2003 Jan; 55(1):94-9. PubMed ID: 12534645
[TBL] [Abstract][Full Text] [Related]
11. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
[TBL] [Abstract][Full Text] [Related]
12. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.
Martin PD; Warwick MJ; Dane AL; Brindley C; Short T
Clin Ther; 2003 Oct; 25(10):2553-63. PubMed ID: 14667956
[TBL] [Abstract][Full Text] [Related]
13. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.
Samineni D; Desai PB; Sallans L; Fichtenbaum CJ
J Clin Pharmacol; 2012 Jun; 52(6):922-31. PubMed ID: 21712498
[TBL] [Abstract][Full Text] [Related]
14. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics.
Simonson SG; Martin PD; Mitchell PD; Lasseter K; Gibson G; Schneck DW
J Clin Pharmacol; 2005 Aug; 45(8):927-34. PubMed ID: 16027403
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study.
Zhang W; Deng S; Chen XP; Zhou G; Xie HT; He FY; Cao D; Li YJ; Zhou HH
Clin Ther; 2008 Jul; 30(7):1283-9. PubMed ID: 18691987
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
[TBL] [Abstract][Full Text] [Related]
18. The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics.
Martin PD; Schneck DW; Dane AL; Warwick MJ
Curr Med Res Opin; 2008 Apr; 24(4):1231-5. PubMed ID: 18355422
[TBL] [Abstract][Full Text] [Related]
19. The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive.
Simonson SG; Martin PD; Warwick MJ; Mitchell PD; Schneck DW
Br J Clin Pharmacol; 2004 Mar; 57(3):279-86. PubMed ID: 14998424
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
Li XN; Xu HR; Chen WL; Chu NN; Zhu JR
Clin Ther; 2010 Mar; 32(3):575-87. PubMed ID: 20399994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
